{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T07:34:43Z","timestamp":1783668883672,"version":"3.55.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Osteosarcoma is a highly malignant bone tumor, and a subset of cases is closely associated with hereditary syndromes. These syndrome-related osteosarcomas exhibit unique clinical features, molecular mechanisms, and therapeutic challenges. This review summarizes the current understanding of specific types of syndrome-related osteosarcomas, including those associated with Rothmund-Thomson syndrome, Li-Fraumeni syndrome, secondary osteosarcoma in retinoblastoma survivors, Werner syndrome, and Bloom syndrome. These syndromes are typically characterized by specific gene mutations or chromosomal instability, significantly increasing the risk of osteosarcoma development. However, the rarity and heterogeneity of syndrome-related osteosarcomas pose significant challenges for diagnosis and treatment, including difficulties in early detection, incomplete elucidation of molecular mechanisms, and limitations of conventional therapeutic approaches. This article aims to systematically review the clinical characteristics, molecular mechanisms, and therapeutic challenges of these syndromes, providing a comprehensive reference for clinicians and directions for future research.<\/jats:p>","DOI":"10.1186\/s13023-026-04243-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T19:05:48Z","timestamp":1770404748000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unraveling syndrome-driven osteosarcoma: genetic insights and therapeutic frontiers"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6794-8395","authenticated-orcid":false,"given":"Yang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laihua","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songfeng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"5","key":"4243_CR1","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jamaoncol.2020.0197","volume":"6","author":"L Mirabello","year":"2020","unstructured":"Mirabello L, Zhu B, Koster R, et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma. JAMA Oncol. 2020;6(5):724\u201334.","journal-title":"JAMA Oncol"},{"issue":"8","key":"4243_CR2","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nrendo.2017.16","volume":"13","author":"DM Gianferante","year":"2017","unstructured":"Gianferante DM, Mirabello L, Savage SA. Germline and somatic genetics of osteosarcoma - connecting aetiology, biology and therapy. Nat Rev Endocrinol. 2017;13(8):480\u201391.","journal-title":"Nat Rev Endocrinol"},{"issue":"23","key":"4243_CR3","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1002\/cncr.30248","volume":"122","author":"PL Mai","year":"2016","unstructured":"Mai PL, Best AF, Peters JA, et al. Risks of first and subsequent cancers among TP53 mutation carriers in the national cancer institute Li-Fraumeni syndrome cohort. Cancer. 2016;122(23):3673\u201381.","journal-title":"Cancer"},{"issue":"1","key":"4243_CR4","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1038\/s41467-020-14646-w","volume":"11","author":"J Wu","year":"2020","unstructured":"Wu J, Lu C, Wang Z, et al. Immuno-genomic landscape of osteosarcoma. Nat Commun. 2020;11(1):1008.","journal-title":"Nat Commun"},{"issue":"6","key":"4243_CR5","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1042\/BST20190492","volume":"48","author":"ID Hickson","year":"2020","unstructured":"Hickson ID, Wu Z. RECQL4 helicase in DNA repair and cancer. Biochem Soc Trans. 2020;48(6):2399\u2013408.","journal-title":"Biochem Soc Trans"},{"issue":"12","key":"4243_CR6","doi-asserted-by":"crossref","first-page":"152697","DOI":"10.1016\/j.prp.2019.152697","volume":"215","author":"D Sekar","year":"2019","unstructured":"Sekar D, Mani P, Biruntha M, et al. Dissecting the role of miR-21 in different types of cancer. Pathol Res Pract. 2019;215(12):152697.","journal-title":"Pathol Res Pract"},{"key":"4243_CR7","doi-asserted-by":"publisher","first-page":"1456959","DOI":"10.3389\/fonc.2024.1456959","volume":"14","author":"Y Ding","year":"2025","unstructured":"Ding Y, Chen Q. Wnt\/\u03b2-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma. Front Oncol. 2025;14:1456959.","journal-title":"Front Oncol"},{"issue":"9","key":"4243_CR8","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1016\/j.humpath.2015.05.019","volume":"46","author":"JY Liau","year":"2015","unstructured":"Liau JY, Tsai JH, Yang CY, et al. Alternative lengthening of telomeres phenotype in malignant vascular tumors is highly associated with loss of ATRX expression and is frequently observed in hepatic angiosarcomas. Hum Pathol. 2015;46(9):1360\u201366.","journal-title":"Hum Pathol"},{"issue":"4","key":"4243_CR9","doi-asserted-by":"publisher","first-page":"180018","DOI":"10.1098\/rsob.180018","volume":"8","author":"\u00d6 \u00d6zer","year":"2018","unstructured":"\u00d6zer \u00d6, Hickson ID. Pathways for maintenance of telomeres and common fragile sites during DNA replication stress. Open Biol. 2018;8(4):180018.","journal-title":"Open Biol"},{"issue":"1","key":"4243_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1074\/jbc.M111.295063","volume":"287","author":"AK Ghosh","year":"2012","unstructured":"Ghosh AK, Rossi ML, Singh DK, et al. RECQL4, the protein mutated in Rothmund-Thomson syndrome, functions in telomere maintenance. J Biol Chem. 2012;287(1):196\u2013209.","journal-title":"J Biol Chem"},{"issue":"9","key":"4243_CR11","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1093\/jnci\/95.9.669","volume":"95","author":"LL Wang","year":"2003","unstructured":"Wang LL, Gannavarapu A, Kozinetz CA, et al. Association between osteosarcoma and deleterious mutations in the RECQL4 gene in Rothmund-Thomson syndrome. J Natl Cancer Inst. 2003;95(9):669\u201374.","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"4243_CR12","first-page":"4083","volume":"16","author":"H He","year":"2018","unstructured":"He H, Ni J, Huang J. Molecular mechanisms of chemoresistance in osteosarcoma. Oncol Lett. 2018;16(4):4083\u201392.","journal-title":"Oncol Lett"},{"issue":"10","key":"4243_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41431-020-0638-4","volume":"28","author":"T Frebourg","year":"2020","unstructured":"Frebourg T, Bajalica Lagercrantz S, Oliveira C, et al. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes. Eur J Hum Genet. 2020;28(10):1379\u201386.","journal-title":"Eur J Hum Genet"},{"issue":"1","key":"4243_CR14","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/s12943-024-02105-9","volume":"23","author":"S Yu","year":"2024","unstructured":"Yu S, Yao X. Advances on immunotherapy for osteosarcoma. Mol Cancer. 2024;23(1):192.","journal-title":"Mol Cancer"},{"key":"4243_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1750-1172-5-2","volume":"5","author":"L Larizza","year":"2010","unstructured":"Larizza L, Roversi G, Volpi L. Rothmund-Thomson syndrome. Orphanet J Rare Dis. 2010;5:2.","journal-title":"Orphanet J Rare Dis"},{"key":"4243_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/978-3-030-43085-6_3","volume":"1258","author":"L Lu","year":"2020","unstructured":"Lu L, Jin W, Wang LL. RECQ DNA helicases and osteosarcoma. Adv Exp Med Biol. 2020;1258:37\u201354.","journal-title":"Adv Exp Med Biol"},{"issue":"6","key":"4243_CR17","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1002\/ajmg.a.33427","volume":"152A","author":"T Simon","year":"2010","unstructured":"Simon T, Kohlhase J, Wilhelm C, et al. Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: case report and literature review. Am J Med Genet A. 2010;152A(6):1575\u201379.","journal-title":"Am J Med Genet A"},{"key":"4243_CR18","doi-asserted-by":"crossref","unstructured":"Salih A, Inoue S, Onwuzurike N. Rothmund-Thomson syndrome (RTS) with osteosarcoma due to RECQL4 mutation. BMJ Case Rep. 2018. 2018;bcr2017222384.","DOI":"10.1136\/bcr-2017-222384"},{"key":"4243_CR19","doi-asserted-by":"publisher","first-page":"1296409","DOI":"10.3389\/fragi.2023.1296409","volume":"4","author":"DJ Martins","year":"2023","unstructured":"Martins DJ, Di Lazzaro Filho R, Bertola DR, Hoch NC. Rothmund-Thomson Syndrome, a disorder far from solved. Front Aging. 2023;4:1296409.","journal-title":"Front Aging"},{"key":"4243_CR20","unstructured":"Schonfeld SJ, Kleinerman RA, Abramson DH, et al. Late effects in survivors of high-risk retinoblastoma: second primary cancers. Pediatr Blood Cancer. 2021;68(10):e29206."},{"issue":"10","key":"4243_CR21","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1080\/14737140.2025.2532110","volume":"25","author":"da Silva Amp","year":"2025","unstructured":"da Silva Amp, Cunha Amaral D, Carneiro Filho LF, et al. Risk factors for secondary neoplasms in retinoblastoma survivors: a systematic literature review. Expert Rev Anticancer Ther. 2025;25(10):1195\u2013202.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"4243_CR22","first-page":"239","volume":"5","author":"M Goto","year":"1996","unstructured":"Goto M, Miller RW, Ishikawa Y, Sugano H. Excess of rare cancers in Werner syndrome (adult progeria). Cancer Epidemiol Biomarker Prev. 1996;5(4):239\u201346.","journal-title":"Cancer Epidemiol Biomarker Prev"},{"issue":"12","key":"4243_CR23","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1111\/j.1349-7006.2000.tb00924.x","volume":"91","author":"Y Ishikawa","year":"2000","unstructured":"Ishikawa Y, Miller RW, Machinami R, Sugano H, Goto M. Atypical osteosarcomas in Werner syndrome (adult progeria). Jpn J Cancer Res. 2000;91(12):1345\u201349.","journal-title":"Jpn J Cancer Res"},{"issue":"9","key":"4243_CR24","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1002\/ajmg.a.40374","volume":"176","author":"C Cunniff","year":"2018","unstructured":"Cunniff C, Djavid AR, Carrubba S, et al. Health supervision for people with Bloom syndrome. Am J Med Genet A. 2018;176(9):1872\u201381.","journal-title":"Am J Med Genet A"},{"issue":"1","key":"4243_CR25","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/8788","volume":"22","author":"S Kitao","year":"1999","unstructured":"Kitao S, Shimamoto A, Goto M, et al. Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome. Nat Genet. 1999;22(1):82\u201384.","journal-title":"Nat Genet"},{"issue":"3","key":"4243_CR26","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1111\/j.1474-9726.2010.00562.x","volume":"9","author":"DK Singh","year":"2010","unstructured":"Singh DK, Karmakar P, Aamann M, et al. The involvement of human RECQL4 in DNA double-strand break repair. Aging Cell. 2010;9(3):358\u201371.","journal-title":"Aging Cell"},{"key":"4243_CR27","doi-asserted-by":"crossref","unstructured":"Maciaszek JL, Oak N, Chen W, et al. Enrichment of heterozygous germline RECQL4 loss-of-function variants in pediatric osteosarcoma. Cold Spring Harb Mol Case Stud. 2019;5(5):a004218.","DOI":"10.1101\/mcs.a004218"},{"key":"4243_CR28","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.arr.2016.06.002","volume":"33","author":"L Lu","year":"2017","unstructured":"Lu L, Jin W, Wang LL. Aging in Rothmund-Thomson syndrome and related RECQL4 genetic disorders. Ageing Res Rev. 2017;33:30\u201335.","journal-title":"Ageing Res Rev"},{"issue":"3\u20134","key":"4243_CR29","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1615\/CritRevOncog.2015013713","volume":"20","author":"JJ Morrow","year":"2015","unstructured":"Morrow JJ, Khanna C. Osteosarcoma genetics and epigenetics: emerging biology and candidate therapies. Crit Rev Oncog. 2015;20(3\u20134):173\u201397.","journal-title":"Crit Rev Oncog"},{"key":"4243_CR30","doi-asserted-by":"crossref","unstructured":"Ng AJM, Walia MK, Smeets MF, et al. The DNA helicase recql4 is required for normal osteoblast expansion and osteosarcoma formation. PLoS Genet. 2015;11(4):e1005160.","DOI":"10.1371\/journal.pgen.1005160"},{"issue":"4","key":"4243_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1177\/1947601911413466","volume":"2","author":"D Malkin","year":"2011","unstructured":"Malkin D. Li-Fraumeni syndrome. Genes Cancer. 2011;2(4):475\u201384.","journal-title":"Genes Cancer"},{"key":"4243_CR32","doi-asserted-by":"crossref","unstructured":"Guha T, Malkin D. Inherited TP53 mutations and the Li-Fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;7(4):a026187.","DOI":"10.1101\/cshperspect.a026187"},{"key":"4243_CR33","doi-asserted-by":"crossref","unstructured":"Kratz CP, Achatz MI, Brugi\u00e8res L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23(11):e38\u201345.","DOI":"10.1158\/1078-0432.CCR-17-0408"},{"issue":"10","key":"4243_CR34","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1200\/JCO.2005.05.054","volume":"23","author":"RA Kleinerman","year":"2005","unstructured":"Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23(10):2272\u201379.","journal-title":"J Clin Oncol"},{"issue":"24","key":"4243_CR35","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1056\/NEJMoa1508054","volume":"373","author":"J Zhang","year":"2015","unstructured":"Zhang J, Walsh MF, Wu G, et al. Germline mutations in predisposition genes in pediatric cancer. N Engl J Med. 2015;373(24):2336\u201346.","journal-title":"N Engl J Med"},{"issue":"29","key":"4243_CR36","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1200\/JCO.2013.54.7844","volume":"32","author":"JR Wong","year":"2014","unstructured":"Wong JR, Morton LM, Tucker MA, et al. Risk of subsequent malignant neoplasms in long-term hereditary retinoblastoma survivors after chemotherapy and radiotherapy. J Clin Oncol. 2014;32(29):3284\u201390.","journal-title":"J Clin Oncol"},{"issue":"8","key":"4243_CR37","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1091\/mbc.10.8.2655","volume":"10","author":"RA Shamanna","year":"1999","unstructured":"Shamanna RA, Croteau DL, Lee JH, Bohr VA. The Werner syndrome protein is involved in RNA polymerase II transcription. Mol Biol Cell. 1999;10(8):2655\u201368.","journal-title":"Mol Biol Cell"},{"key":"4243_CR38","doi-asserted-by":"crossref","unstructured":"Lauper JM, Krause A, Vaughan TL, Monnat RJ Jr. Spectrum and risk of neoplasia in Werner syndrome: a systematic review. PLoS One. 2013;8(4):e59709.","DOI":"10.1371\/journal.pone.0059709"},{"issue":"16","key":"4243_CR39","doi-asserted-by":"publisher","first-page":"6548","DOI":"10.1158\/0008-5472.CAN-10-0475","volume":"70","author":"FJ Mao","year":"2020","unstructured":"Mao FJ, Sidorova JM, Lauper JM, et al. The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage. Cancer Res. 2020;70(16):6548\u201355.","journal-title":"Cancer Res"},{"key":"4243_CR40","doi-asserted-by":"crossref","unstructured":"Ellis NA, German J. Molecular genetics of Bloom\u2019s syndrome. Hum Mol Genet. 1996, 5 Spec: No, 1457-1463.","DOI":"10.1093\/hmg\/5.Supplement_1.1457"},{"key":"4243_CR41","unstructured":"Flanagan M, Cunniff CM Bloom syndrome. in: Pagon RA, Adam MP, Ardinger HH, et al, editors. GeneReviews\u00ae. Seattle: University of Washington; 2023."},{"issue":"1","key":"4243_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2005.04.023","volume":"236","author":"M Amor-Gu\u00e9ret","year":"2006","unstructured":"Amor-Gu\u00e9ret M. Bloom syndrome, genomic instability and cancer: the SOS-like hypothesis. Cancer Lett. 2006;236(1):1\u201312.","journal-title":"Cancer Lett"},{"issue":"1","key":"4243_CR43","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/S0165-4608(96)00336-6","volume":"93","author":"J German","year":"1997","unstructured":"German J. Bloom\u2019s syndrome. XX. The first 100 cancers. Cancer Genet Cytogenet. 1997;93(1):100\u201306.","journal-title":"Cancer Genet Cytogenet"},{"issue":"4","key":"4243_CR44","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1200\/JCO.2006.08.4558","volume":"25","author":"MJ Hicks","year":"2007","unstructured":"Hicks MJ, Roth JR, Kozinetz CA, Wang LL. Clinicopathologic features of osteosarcoma in patients with Rothmund-Thomson syndrome. J Clin Oncol. 2007;25(4):370\u201375.","journal-title":"J Clin Oncol"},{"issue":"23","key":"4243_CR45","doi-asserted-by":"publisher","first-page":"14939","DOI":"10.3390\/ijms232314939","volume":"23","author":"L Pekarek","year":"2022","unstructured":"Pekarek L, De la Torre-Escuredo B, Fraile-Martinez O, et al. Towards the search for potential biomarkers in osteosarcoma: state-of-the-art and translational expectations. Int J Mol Sci. 2022;23(23):14939.","journal-title":"Int J Mol Sci"},{"issue":"9","key":"4243_CR46","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1007\/s00247-018-4113-0","volume":"48","author":"MC Greer","year":"2018","unstructured":"Greer MC. Imaging of cancer predisposition syndromes. Pediatr Radiol. 2018;48(9):1364\u201375.","journal-title":"Pediatr Radiol"},{"key":"4243_CR47","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1146\/annurev-biochem-060815-014710","volume":"85","author":"AC Joerger","year":"2016","unstructured":"Joerger AC, Fersht AR. The p53 pathway: origins, inactivation in Cancer, and emerging therapeutic approaches. Annu Rev Biochem. 2016;85:375\u2013404.","journal-title":"Annu Rev Biochem"},{"issue":"11","key":"4243_CR48","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1001\/jamaophthalmol.2015.3108","volume":"133","author":"DH Abramson","year":"2015","unstructured":"Abramson DH, Shields CL, Munier FL, et al. Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmol. 2015;133(11):1341\u201347.","journal-title":"JAMA Ophthalmol"},{"key":"4243_CR49","doi-asserted-by":"publisher","first-page":"108456","DOI":"10.1016\/j.exer.2021.108456","volume":"205","author":"P Chai","year":"2021","unstructured":"Chai P, Luo Y, Yu J, et al. Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: a dual-center study of 145 patients. Exp Eye Res. 2021;205:108456.","journal-title":"Exp Eye Res"},{"issue":"5","key":"4243_CR50","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/ejhg.2011.265","volume":"20","author":"FM Hisama","year":"2012","unstructured":"Hisama FM, Kubisch C, Martin GM, Oshima J. Clinical utility gene card for: werner syndrome. Eur J Hum Genet. 2012;20(5):497.","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"4243_CR51","first-page":"810","volume":"19","author":"M Khraishi","year":"1992","unstructured":"Khraishi M, Howard B, Little H. A patient with Werner\u2019s syndrome and osteosarcoma presenting as scleroderma. J Rheumatol. 1992;19(5):810\u201313.","journal-title":"J Rheumatol"},{"issue":"6","key":"4243_CR52","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/j.cell.2017.08.028","volume":"170","author":"ER Kastenhuber","year":"2017","unstructured":"Kastenhuber ER, Lowe SW. Putting p53 in context. Cell. 2017;170(6):1062\u201378.","journal-title":"Cell"},{"issue":"1","key":"4243_CR53","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.celrep.2014.03.003","volume":"7","author":"X Chen","year":"2014","unstructured":"Chen X, Bahrami A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. Cell Rep. 2014;7(1):104\u201312.","journal-title":"Cell Rep"},{"key":"4243_CR54","unstructured":"Perry JA, Kiezun A, Tonzi P, et al. Complementary genomic approaches highlight the PI3K\/mTOR pathway as a common vulnerability in osteosarcoma. Proc Natl Acad Sci U S A. 2014;111(51):E5564\u201373."},{"key":"4243_CR55","doi-asserted-by":"crossref","unstructured":"Iyer DR, Harada N, Clairmont C, et al. CCAR2 functions downstream of the shieldin complex to promote double-strand break end-joining. Proc Natl Acad Sci U S A. 2022;119(49):e2214935119.","DOI":"10.1073\/pnas.2214935119"},{"key":"4243_CR56","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1186\/1471-2407-13-187","volume":"13","author":"J Giacomazzi","year":"2013","unstructured":"Giacomazzi J, Selistre S, Duarte J, et al. TP53 p.R337H is a conditional cancer-predisposing mutation: further evidence from a homozygous patient. BMC Cancer. 2013;13:187.","journal-title":"BMC Cancer"},{"issue":"3","key":"4243_CR57","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41588-019-0576-7","volume":"52","author":"I Cort\u00e9s-Ciriano","year":"2020","unstructured":"Cort\u00e9s-Ciriano I, Lee JJ, Xi R, et al. Comprehensive analysis of chromothripsis in 2, 658 human cancers using whole-genome sequencing. Nat Genet. 2020;52(3):331\u201341.","journal-title":"Nat Genet"},{"issue":"7689","key":"4243_CR58","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature25432","volume":"553","author":"SF Bakhoum","year":"2018","unstructured":"Bakhoum SF, Ngo B, Laughney AM, et al. Chromosomal instability drives metastasis through a cytosolic DNA response. Nature. 2018;553(7689):467\u201372.","journal-title":"Nature"},{"key":"4243_CR59","doi-asserted-by":"crossref","unstructured":"Kratz CP, Achatz MI, Brugi\u00e8res L, et al. Cancer screening recommendations for individuals with Li-Fraumeni syndrome. Clin Cancer Res. 2017;23(13):e38\u201345.","DOI":"10.1158\/1078-0432.CCR-17-0408"},{"issue":"9","key":"4243_CR60","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S1470-2045(16)30147-4","volume":"17","author":"ML Ballinger","year":"2016","unstructured":"Ballinger ML, Goode DL, Ray-Coquard I, et al. Monogenic and polygenic determinants of sarcoma risk: an international genetic study. Lancet Oncol. 2016;17(9):1261\u201371.","journal-title":"Lancet Oncol"},{"issue":"8","key":"4243_CR61","doi-asserted-by":"publisher","first-page":"538","DOI":"10.31128\/AJGP-04-21-5954","volume":"50","author":"R Forbes Shepherd","year":"2021","unstructured":"Forbes Shepherd R, Keogh LA, Werner-Lin A, Delatycki MB, Forrest LE. Benefits and burdens of risk management for young people with inherited cancer: a focus on Li-Fraumeni syndrome. Aust J Gen Pract. 2021;50(8):538\u201344.","journal-title":"Aust J Gen Pract"},{"issue":"9","key":"4243_CR62","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(16)30249-2","volume":"17","author":"A Villani","year":"2016","unstructured":"Villani A, Shore A, Wasserman JD, et al. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11-year follow-up of a prospective observational study. Lancet Oncol. 2016;17(9):1295\u2013305.","journal-title":"Lancet Oncol"},{"issue":"13","key":"4243_CR63","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1101\/gad.282145.116","volume":"30","author":"NJ Dyson","year":"2016","unstructured":"Dyson NJ. RB1: a prototype tumor suppressor and an enigma. Genes Dev. 2016;30(13):1492\u2013502.","journal-title":"Genes Dev"},{"issue":"2","key":"4243_CR64","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S1097-2765(01)00327-6","volume":"8","author":"DM Thomas","year":"2001","unstructured":"Thomas DM, Carty SA, Piscopo DM, et al. The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation. Mol Cell. 2001;8(2):303\u201316.","journal-title":"Mol Cell"},{"issue":"38","key":"4243_CR65","doi-asserted-by":"publisher","first-page":"5220","DOI":"10.1038\/sj.onc.1209615","volume":"25","author":"C Giacinti","year":"2006","unstructured":"Giacinti C, Giordano A. RB and cell cycle progression. Oncogene. 2006;25(38):5220\u201327.","journal-title":"Oncogene"},{"issue":"7310","key":"4243_CR66","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/nature09264","volume":"466","author":"E Calo","year":"2010","unstructured":"Calo E, Quintero-Estades JA, Danielian PS, Nedelcu S, Berman SD, Lees JA. Rb regulates fate choice and lineage commitment in vivo. Nature. 2010;466(7310):1110\u201314.","journal-title":"Nature"},{"issue":"6","key":"4243_CR67","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/j.cell.2007.03.055","volume":"129","author":"CR Walkley","year":"2007","unstructured":"Walkley CR, Shea JM, Sims NA, Purton LE, Orkin SH. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell. 2007;129(6):1081\u201395.","journal-title":"Cell"},{"issue":"1","key":"4243_CR68","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/2045-3329-2-15","volume":"2","author":"RA Kleinerman","year":"2012","unstructured":"Kleinerman RA, Schonfeld SJ, Tucker MA. Sarcomas in hereditary retinoblastoma. Clin Sarcoma Res. 2012;2(1):15.","journal-title":"Clin Sarcoma Res"},{"issue":"1","key":"4243_CR69","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1002\/cncr.28387","volume":"120","author":"RV Sethi","year":"2014","unstructured":"Sethi RV, Shih HA, Yeap BY, et al. Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer. 2014;120(1):126\u201333.","journal-title":"Cancer"},{"issue":"2","key":"4243_CR70","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.ijrobp.2023.07.025","volume":"119","author":"DL Casey","year":"2024","unstructured":"Casey DL, Vogelius IR, Brodin NP, et al. Risk of subsequent neoplasms in childhood Cancer survivors after radiation therapy: a PENTEC Comprehensive review. Int J Radiat Oncol Biol Phys. 2024;119(2):640\u201354.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"4243_CR71","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/pbc.26193","volume":"64","author":"P Temming","year":"2017","unstructured":"Temming P, Arendt M, Viehmann A, et al. Incidence of second cancers after radiotherapy and systemic chemotherapy in hereditary retinoblastoma survivors: a report from the German reference center. Pediatr Blood Cancer. 2017;64(1):71\u201380.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"4243_CR72","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.ajo.2015.09.009","volume":"160","author":"de Jong MC","year":"2015","unstructured":"de Jong MC, Kors WA, de Graaf P, et al. The incidence of trilateral retinoblastoma: a systematic review and meta-analysis. Am J Ophthalmol. 2015;160(6):1116\u201326.","journal-title":"Am J Ophthalmol"},{"key":"4243_CR73","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.arr.2016.03.002","volume":"33","author":"J Oshima","year":"2017","unstructured":"Oshima J, Sidorova JM, Monnat RJ Jr. Werner syndrome: clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev. 2017;33:105\u201314.","journal-title":"Ageing Res Rev"},{"key":"4243_CR74","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3389\/fgene.2013.00129","volume":"4","author":"B Saha","year":"2013","unstructured":"Saha B, Zitnik G, Johnson S, et al. DNA damage accumulation and TRF2 degradation in atypical Werner syndrome fibroblasts with LMNA mutations. Front Genet. 2013;4:129.","journal-title":"Front Genet"},{"issue":"1","key":"4243_CR75","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41572-022-00409-y","volume":"8","author":"HC Beird","year":"2022","unstructured":"Beird HC, Bielack SS, Flanagan AM, et al. Osteosarcoma. Nat Rev Dis Primers. 2022;8(1):77.","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"4243_CR76","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP. ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell. 2017;66(6):801\u201317.","journal-title":"Mol Cell"},{"key":"4243_CR77","doi-asserted-by":"crossref","unstructured":"Pacaud C, Nazon C, Pages M, et al. Management of paediatric cancers associated with Bloom syndrome. Hum Mutat. 2025. 2025;7065233.","DOI":"10.1155\/humu\/7065233"},{"issue":"12","key":"4243_CR78","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","volume":"32","author":"SJ Strauss","year":"2021","unstructured":"Strauss SJ, Frezza AM, Abecassis N, et al. Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(12):1520\u201336.","journal-title":"Ann Oncol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04243-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04243-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04243-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:06:36Z","timestamp":1773151596000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04243-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4243"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04243-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"20 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"97"}}